

**5** Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 59388

Manuscript Type: CASE REPORT

**Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report**

Pembrolizumab for Refractory Thymic Epithelial Carcinoma

Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssièrè, Xavier Durando

## Match Overview

1	Crossref 34 words Giuseppe Giaccone, Chul Kim, Jillian Thompson, Colleen McGuire et al. "Pembrolizumab in patients with thymic c...	2%
2	Crossref 25 words Jinhyun Cho, Hae Su Kim, Bo Mi Ku, Yoon-La Choi et al. "Pembrolizumab for Patients With Refractory or Relapse...	1%
3	Internet 18 words crawled on 29-Sep-2020 <a href="http://www.wjgnet.com">www.wjgnet.com</a>	1%
4	Internet 14 words crawled on 03-May-2009 <a href="http://www.ncchta.org">www.ncchta.org</a>	1%
5	Internet 14 words crawled on 27-Oct-2020 <a href="http://f6publishing.blob.core.windows.net">f6publishing.blob.core.windows.net</a>	1%
6	Internet 13 words crawled on 10-Aug-2020 <a href="http://mafiadoc.com">mafiadoc.com</a>	1%

激活 Windows

转到“设置”以激活 Windows

Text-Only Report

Pembrolizumab as a novel therapeutic option for patients with refractor

ALL IMAGES VIDEOS

63,500 Results Any time

**R<sup>6</sup>** (PDF) Pembrolizumab combined with lenvatinib as non ...

<https://www.researchgate.net/publication/343469372...>

Background: A **therapeutic strategy** involving combined **treatment** with **lenvatinib** plus **pembrolizumab (LEP)** has demonstrated a relatively **high antitumor** response in several **solid tumors...**

**BMJ** Phase 2 study of pembrolizumab in patients with advanced ...

<https://jitc.bmj.com/content/8/1/e000347>

Mar 01, 2020 · Background **Patients** with advanced rare cancers have poor prognosis and few treatment **options**. As immunotherapy is effective across multiple cancer types, we aimed to assess **pembrolizumab** (programmed cell death 1 (PD-1) inhibitor) in **patients** with advanced rare cancers. Methods In this open-label, phase 2 trial, **patients** with advanced rare cancers whose tumors had ...

**Cited by:** 6      **Author:** Aung Naing, Funda Meric-Bernstam, Bett...  
**Publish Year:** 2020

Search Tools  
Turn off Hover Translation (关闭取



ALL

IMAGES

VIDEOS

64,700 Results

Any time ▾

### [Full text] The Effect and Safety of Anti-PD-1 Single ...

<https://www.dovepress.com/the-effect-and-safety-of...> ▾

The Effect and Safety of Anti-PD-1 Single/Combination **Therapy** in **Refractory Thymic Carcinoma: A Case-Series Study** Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.

### 775 Rare case reports on thymic carcinoma patients treated ...

[https://jitc.bmj.com/content/8/Suppl\\_3/A825](https://jitc.bmj.com/content/8/Suppl_3/A825) ▾

Background Thymomas and **thymic carcinomas** (TC) are intrathoracic malignancies that, although rare, represent the most common anterior mediastinal tumors in adults (comprising approximately 0.2-1.5% of all malignancies).<sup>1</sup> Recent accumulating evidence on immune checkpoint pathways suggests that immunotherapy might be a promising **therapeutic option** for **refractory** TCs.<sup>2</sup> We herein **report** two ...

### Phase 2 study of pembrolizumab in patients with advanced ...

<https://jitc.bmj.com/content/8/1/e000347> ▾

Mar 01, 2020 · An ORR of 42% at 15 weeks has been reported with pembrolizumab as first line of therapy in 17 evaluable patients with **unresectable SCC of skin**.<sup>19</sup> In another study, an ORR of 40% has been reported in 10 patients with **metastatic SCC of skin**, majority of whom have not received prior systemic ...

## Search Tools

Turn on Hover Translation (开启取词)

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

63,300 Results

Any time ▾

### [Case report: impressive response to pembrolizumab in a ...](#)

<https://esmoopen.bmj.com/content/1/6/e000084> ▾

Dec 01, 2016 · Here, we **report** the history of a 42-year-old female **patient** with sporadic mismatch-repair-deficient metastatic colorectal cancer and abdominal bulky disease, who received **pembrolizumab** (200 mg every 3 weeks) after the failure of third-line treatment. Restaging 3 months after initiation of treatment revealed a striking response with shrinkage of the bulky peritoneal tumour mass (baseline size ...

**Cited by:** 6**Author:** Markus Kieler, Werner Scheithauer, Christo...**Publish Year:** 2016

### [775 Rare case reports on thymic carcinoma patients treated ...](#)

[https://jitc.bmj.com/content/8/Suppl\\_3/A825](https://jitc.bmj.com/content/8/Suppl_3/A825) ▾

Background Thymomas and **thymic carcinomas** (TC) are intrathoracic malignancies that, although rare, represent the most common anterior mediastinal tumors in adults (comprising approximately 0.2-1.5% of all malignancies).<sup>1</sup> Recent accumulating evidence on immune checkpoint pathways suggests that immunotherapy might be a promising **therapeutic option** for **refractory** TCs.<sup>2</sup> We herein **report** two ...

### [\[Full text\] The Effect and Safety of Anti-PD-1 Single ...](#)

<https://www.dovepress.com/the-effect-and-safety-of...> ▾

The Effect and Safety of Anti-PD-1 Single/Combination **Therapy** in **Refractory Thymic Carcinoma: A Case-Series Study** Javascript is currently disabled in your browser. Several features of this site will not function whilst javascript is disabled.

**Author:** Wei Jin, Jian-Chun Duan, Zhi-Jie Wang, ... **Publish Year:** 2020

### [Phase 2 study of pembrolizumab in patients with advanced ...](#)

<https://jitc.bmj.com/content/8/1/e000347> ▾

Mar 01, 2020 · An ORR of 42% at 15 weeks has been reported with pembrolizumab as first line of therapy in 17 evaluable patients with **unresectable SCC of skin**.<sup>19</sup> In another study, an ORR of 40% has been reported in 10 patients with **metastatic SCC of skin**, majority of whom have not received prior systemic therapy.<sup>20</sup> Thus, findings from our study (ORR of 31% and CBR of 38%) is noteworthy given that all of ...

**Cited by:** 6**Author:** Aung Naing, Funda Meric-Bernstam, Bettzy...**Publish Year:** 2020